ALMS Overview

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is37.57 USD with a low forecast of 32.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alumis Inc revenue for the last quarter amounts to 2.07M USD, decreased

Alumis Inc. EPS for the last quarter amounts to -1.06 USD, decreased -38.01

Alumis Inc (ALMS) has 168 emplpoyees as of March 12 2026.

Today ALMS has the market capitalization of 3.21B USD.